Clinical Trial Update: A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2, prospective, single-arm, open-label study of CM313 in immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• CM313

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 2 | Status: COMPLETED